Recombinant Teriparatide for Injection Market Forecast 2026–2034: Trends & Insights According to a newly published market research report by 24LifeSciences, global recombinant teriparatide for injection market was valued at USD 245.7 million in 2025 and is projected to reach USD 398.3 million by 2034, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period 2026–2034. Recombinant teriparatide, clinically known as Forteo, is a synthetic 34-amino acid peptide analog of human parathyroid hormone (PTH) produced through recombinant DNA technology. As the first FDA-approved anabolic bone therapy, it stimulates new bone formation by enhancing osteoblast activity, making it particularly effective for treating severe osteoporosis, glucocorticoid-induced osteoporosis, and postmenopausal osteoporosis with high fracture risk. Its unique mechanism contrasts with conventional antiresorptive treatments by actually building bone mass rather than just preventing bone loss. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15420/recombinant-teriparatide-for-injection-market